 EXPENDITURES FOR MEDICINES, PAID BY NHIF IN ACCORDANCE WITH THE HEALTH INSURANCE LAW – STATUS AND TRENDSSilvia Terezova and
Mariya Vasileva ()
Conferences of the department "Economics and Management of Trade", 2023, issue 1, 107-113 Abstract: The medicinal products prices regulation is one of the mechanisms for reduction the publics costs. External and internal price referencing applies. The dynamics of the public expenditures changes for the medicinal products included in the PDL was assessed by month of 2022. Based on the grouping of the annual expenditures by diseases, their structure was evaluated in order to determine the costliest diseases – rare diseases. The impact of changes in the reference value of medicinal products for the treatment of two rare diseases on the NHIF costs was evaluated, by grouping them by INN with the most significant reduction of the reference value during the considered period. Keywords: International non-patent name (INN); National Health Insurance Fund (NHIF); reimbursement value; Positive Drug List (PDL) (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:vrn:commdh:y:2023:i:1:p:107-113 Access Statistics for this article Conferences of the department "Economics and Management of Trade" is currently edited by Miglena Mileva More articles in Conferences of the department "Economics and Management of Trade" from Publishing house "Science and Economics" Varna Contact information at EDIRC. |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.